Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning targeted synthetic and biologic therapy across spondyloarthritis, psoriasis and myositis; treat-to-target and prognostic thinking in lupus, lupus nephritis and IgG4-related disease; and health-system questions about early referral, biosimilars and cancer screening. Let's dive in.

This week's papers:

1. Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies — Annals of the Rheumatic Diseases 2027
2. Biologic DMARD class influences progression from psoriasis to PsA: A real-world cohort study — Rheumatology 2026
3. Long-term effectiveness of the Early Arthritis Recognition Clinic's screening for the presence of clinical arthritis in the Netherlands: a single-centre, longitudinal cohort study — Lancet Rheumatology 2026
4. Cancer-associated myositis in Chinese patients with idiopathic inflammatory myopathies: Malignancy spectrum, risk factors, and validation of the IMACS guideline — Seminars in Arthritis and Rheumatism 2026
5. Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve — Rheumatology 2026
6. Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the veterans health administration — Rheumatology 2026
7. Attainment of early targets does not ensure a complete response at 12 months in lupus nephritis, especially in nephrotic-range proteinuria — Rheumatology 2026
8. Effectiveness and safety of upadacitinib on adult dermatomyositis: a cohort study in China — Seminars in Arthritis and Rheumatism 2026
9. Early haematologic response to anifrolumab in systemic lupus erythematosus: results from the european multicentre EFFORT-SLE study — Rheumatology 2026
10. Treatment strategies for relapsing IgG4-RD: twelve-year experience from a prospective cohort — Rheumatology 2026

Listen at AudioScholar

Welcome to This Week in Rheumatology. This week we're covering 8 notable papers spanning treatment optimisation in rheumatoid arthritis, connective tissue disease lung involvement and guideline navigation, and two very different attempts to move the needle on osteoarthritis pain. Let's dive in.

This week's papers:

1. Navigating evidence-based recommendations for the management of systemic sclerosis — Nature Reviews Rheumatology 2026
2. Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials — The Lancet Rheumatology 2026
3. Effectiveness and safety of interleukin 6 receptor inhibitors versus conventional immunomodulatory therapy in steroid-refractory polymyalgia rheumatica — RMD Open 2026
4. Therapeutic approaches for difficult-to-treat rheumatoid arthritis: a systematic literature review of current evidence — RMD Open 2026
5. Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real-world data from the ILD-PRO Registry — Arthritis & Rheumatology 2026
6. Advances in the treatment of eosinophilic granulomatosis with polyangiitis — Nature Reviews Rheumatology 2026
7. Low Dose Radiation Therapy and Osteoarthritis Pain — Arthritis & Rheumatology 2026
8. Safety, biodistribution, and exploratory clinical outcomes of a novel intra-articular IL-1Ra gene therapy (PCRX-201) in moderate-to-severe knee osteoarthritis: 2-year results of a phase 1 study — Annals of the Rheumatic Diseases 2026

Listen at AudioScholar

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning critical advances in systemic lupus erythematosus, prognostic biomarkers in systemic sclerosis, and evolving therapeutic strategies in inflammatory arthritis, vasculitis, and autoinflammatory conditions. Let's dive in.

This week's papers:

1. Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years. — Annals of the rheumatic diseases 2026
2. Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study. — RMD open 2026
3. Redefining the Landscape: Acquired Mutations Driving Systemic Autoinflammatory Diseases. — Arthritis & rheumatology (Hoboken, N.J.) 2026
4. Circulating biomarkers in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. — Annals of the rheumatic diseases 2026
5. Prognostic value of antiphospholipid antibodies in pregnancy outcomes in systemic lupus erythematosus. — RMD open 2026
6. Prolonged serologically active clinically quiescent systemic lupus erythematosus: a longitudinal study on the role of IgG anti-dsDNA and C3. — Rheumatology (Oxford, England) 2026
7. Anti-carbamylated fibrinogen autoantibodies of IgG and IgA isotypes contribute to a better prognostic stratification in very early rheumatoid arthritis: data from the French national ESPOIR cohort. — Arthritis & rheumatology (Hoboken, N.J.) 2026
8. Risk of falls, recurrent falls and osteoporotic fractures in SLE patients with comorbid fibromyalgia: a propensity score-matched cohort study using the TriNetX Network. — Lupus science & medicine 2026
9. Anakinra for intravenous immunoglobulin-resistant Kawasaki disease: a systematic literature review. — RMD open 2026
10. High levels of Vascular Cell Adhesion Molecule 1 associate with a 'vasculopathic' phenotype in systemic sclerosis with higher mortality. — Rheumatology (Oxford, England) 2026

Listen at AudioScholar

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning targeted biological therapies in vasculitis, novel autoantibody and proteomic biomarkers in connective tissue diseases, and genetic overlap in rheumatoid arthritis. Let's dive in.

This week's papers:

1. Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years. — Annals of the rheumatic diseases 2026
2. Spatial transcriptomics reveals mechanism of autoimmunity driven by internalised autoantibodies. — Annals of the rheumatic diseases 2026
3. High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis. — Annals of the rheumatic diseases 2026
4. High levels of Vascular Cell Adhesion Molecule 1 associate with a "vasculopathic" phenotype in systemic sclerosis with higher mortality. — Rheumatology (Oxford, England) 2026
5. Prolonged serologically active clinically quiescent systemic lupus erythematosus: a longitudinal study on the role of IgG anti-dsDNA and C3. — Rheumatology (Oxford, England) 2026
6. Interferon-related gene expression defines disease activity, organ involvement and treatment response in juvenile dermatomyositis. — Rheumatology (Oxford, England) 2026
7. Characteristics and outcomes of anti-Ku antibody-associated interstitial lung disease: a retrospective study of 60 patients. — RMD open 2026
8. Anti-carbamylated fibrinogen autoantibodies of IgG and IgA isotypes contribute to a better prognostic stratification in very early rheumatoid arthritis: data from the French national ESPOIR cohort. — Arthritis & rheumatology (Hoboken, N.J.) 2026
9. Circulating kidney injury molecule-1 as a prognostic biomarker for long-term renal outcomes in lupus nephritis: a retrospective cohort study. — Lupus science & medicine 2026
10. A genome-wide cross-trait analysis characterises the shared genetic architecture between rheumatoid arthritis and psychiatric disorders. — Rheumatology (Oxford, England) 2026

Listen at AudioScholar

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning vasculitis management, spondyloarthritis therapeutics, rare autoimmune conditions, and early rheumatoid arthritis detection. Let's dive in.

This week's papers:

1. 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis. — Annals of the rheumatic diseases 2026
2. Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial. — Arthritis & rheumatology (Hoboken, N.J.) 2026
3. A phase 2 trial of rilzabrutinib in IgG4-related disease. — Annals of the rheumatic diseases 2026
4. Effects of first-line biologic immunomodulation compared with non-biologic therapies in adult-onset Still's disease: a two-center cohort study. — Arthritis research & therapy 2026
5. Ultrasound-defined presynovitis is associated with progression to clinical arthritis in ACPA-positive individuals at risk of rheumatoid arthritis: longitudinal insights from the Karolinska Risk-RA cohort. — Annals of the rheumatic diseases 2026
6. Lung disease in adult-onset Still's disease: a chinese cohort study. — Rheumatology (Oxford, England) 2026
7. The WORKWELL programme: a randomised controlled trial of job retention vocational rehabilitation for people with inflammatory arthritis. — Rheumatology (Oxford, England) 2026
8. Single-cell analysis identifies monocyte signatures of disease activity and clinical subtypes in Behçet's disease. — Annals of the rheumatic diseases 2026
9. Nutritional interventions and dietary supplements in muscle diseases: a systematic review. — Rheumatology (Oxford, England) 2026
10. Psoriasis patients with psoriatic arthritis demonstrate a reduced regulatory capacity for neutrophil elastase. — Rheumatology (Oxford, England) 2026

Listen at AudioScholar

Welcome to This Week in Rheumatology. This week we are covering ten notable papers spanning three broad themes: novel therapeutic pathways and real-world outcomes in vasculitis and autoinflammatory diseases, optimized screening and patient-reported measures in myositis and lupus, and the broader clinical and socioeconomic contexts of chronic rheumatic care. Let us dive in.

This week's papers:

1. Zanubrutinib monotherapy for IgG4-related head and neck disease. — Annals of the Rheumatic Diseases 2026
2. Real-world efficacy and safety of avacopan in ANCA-associated vasculitis: a retrospective comparative study. — RMD Open 2026
3. Multicentre international audit of IMACS malignancy screening guidelines in idiopathic inflammatory myopathies: insights from the myositis audit and research collaborative group. — RMD Open 2026
4. Risk of cancer induced by human papillomavirus in patients with immune-mediated inflammatory diseases: a nationwide matched cohort study. — RMD Open 2026
5. Fibromyalgia. — The New England Journal of Medicine 2026
6. Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries. — Annals of the Rheumatic Diseases 2026
7. International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) study. — Lupus Science & Medicine 2026
8. Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network. — Rheumatology (Oxford, England) 2026
9. Evaluation of the prognostic value of visual and quantitative CT analysis in myositis-associated interstitial lung disease. — RMD Open 2026
10. Time to diagnosis in large vessel vasculitis: insights from a retrospective study at a tertiary rheumatology centre. — RMD Open 2026

Listen at AudioScholar

Welcome to This Week in Rheumatology. This week we are covering eight notable papers spanning advances in spondyloarthritis diagnosis and tracking, the genetic and therapeutic landscapes of giant cell arteritis, and emerging tools to predict complications in systemic lupus erythematosus, autoinflammatory diseases, and pregnancy. Let us dive in.

This week's papers:

1. Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project — Annals of the Rheumatic Diseases 2026
2. A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus — Annals of the Rheumatic Diseases 2026
3. Enhancing diagnostic accuracy in axial spondyloarthritis through centralised clinical and imaging evaluation: results from a prospective multicentre project — Annals of the Rheumatic Diseases 2026
4. Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database — RMD Open 2026
5. Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study — RMD Open 2026
6. Pediatric macrophage activation syndrome: clinical features and outcomes across diverse etiologies — Rheumatology (Oxford) 2026
7. Development and assessment of an assisted diagnosis model using machine learning for identifying adult-onset Still's disease in fever of unknown origin: a retrospective study in China — RMD Open 2026
8. Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups — Annals of the Rheumatic Diseases 2026

Listen at AudioScholar

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning predicting and preventing disease progression in psoriatic arthritis, cardiorenal management in systemic autoimmune diseases, and novel clinical tools for patient phenotyping and care delivery. Let's dive in.

This week's papers:

1. Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST. — Rheumatology (Oxford, England) 2026
2. Are RAS inhibitors necessary during intensive immunosuppression for lupus nephritis? Real-world evidence from the STAR cohort. — Lupus science & medicine 2026
3. Radiographic Sacroiliitis Progression in Psoriatic Arthritis. — Rheumatology (Oxford, England) 2026
4. Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases. — Rheumatology (Oxford, England) 2026
5. Stability and prognostic value of B-cell markers in primary Sjögren's syndrome: results from the French ASSESS cohort. — Rheumatology (Oxford, England) 2026
6. Clustering-based stratification of fibromyalgia subtypes: A comparative analysis of medicated and non-medicated cohorts from two academic centers. — Seminars in arthritis and rheumatism 2026
7. Personalized, physiotherapist-guided exercise programs in juvenile idiopathic arthritis: home-based vs. immersive virtual reality (JiaFitXR). — Rheumatology (Oxford, England) 2026
8. Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL). — Rheumatology (Oxford, England) 2026
9. Imaging techniques for assessing the hand in systemic sclerosis: a systematic review. — Seminars in arthritis and rheumatism 2026
10. Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project. — Annals of the rheumatic diseases 2026

Listen at AudioScholar

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning emerging cellular and molecular targets in systemic autoimmune diseases, real-world evidence and imaging in inflammatory arthritis, and system-level insights into care pathways and drug regulation. Let's dive in.

This week's papers:

1. Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis — Rheumatology (Oxford, England) 2026
2. Persistence and Effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries — Rheumatology (Oxford, England) 2026
3. Fibroblast Mitochondrial Ca2+ Overload Drives Skin Fibrosis via mtDNA Leakage and cGAS-STING Activation in Systemic Sclerosis — Arthritis & rheumatology (Hoboken, N.J.) 2026
4. Diagnostic Value and Treatment Responsiveness of Ultrasound Features in correlation with clinical findings in Early Peripheral Spondyloarthritis — Arthritis & rheumatology (Hoboken, N.J.) 2026
5. Referral pathways and duration of care for musculoskeletal complaints across Europe: an analysis of primary and secondary care — Annals of the rheumatic diseases 2026
6. Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance — The Lancet. Rheumatology 2026
7. TLR7 in systemic lupus erythematosus: genetics and emerging therapies — Nature reviews. Rheumatology 2026
8. Predictors of unacceptable pain and the impact of sociodemographic factors and comorbidities-results from a large, nationwide cohort of early rheumatoid arthritis — Annals of the rheumatic diseases 2026
9. Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series — Annals of the rheumatic diseases 2026
10. The association between ethnicity, socioeconomic position and outcomes following initiation of TNF inhibitors in Juvenile Idiopathic Arthritis: Results from the UK JIA Biologics Register — Rheumatology (Oxford, England) 2026

Listen at AudioScholar

Welcome to This Week in Rheumatology. This week we're covering 8 notable papers spanning advances in precision monitoring and biomarkers, new insights into long-term risk and disease pathogenesis, and a look at novel therapeutics in related fields. Let's dive in.

This week's papers:

1. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. — The New England journal of medicine 2026
2. Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease. — The New England journal of medicine 2026
3. Longitudinal profiling reveals immune dynamics and distinct plasma cell signatures during B-cell depletion in IgG4-related disease. — Annals of the rheumatic diseases 2026
4. Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy. — Annals of the rheumatic diseases 2026
5. Carotid-femoral pulse wave velocity improves cardiovascular risk prediction beyond SCORE2 in autoimmune rheumatic diseases: a 7-year follow-up study. — RMD open 2026
6. Risk of chronic kidney disease in newly diagnosed systemic lupus erythematosus with preserved renal function: a national study. — Rheumatology (Oxford, England) 2026
7. [Ga]Ga-DOTA-Siglec-9 PET/CT in newly diagnosed giant cell arteritis: an inflammation-specific, treatment-responsive molecular imaging biomarker. — RMD open 2026
8. Monogenic autoimmune and autoinflammatory disorders in adulthood: recent discoveries and implications for rheumatology practice. — Rheumatology (Oxford, England) 2026

Listen at AudioScholar